Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind placebo-controlled study of AVE1625 in mild to moderate Alzheimer's disease
2006-002317-12Phase 2Completed
- Sponsor
- Sanofi
- Start
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OPNT004 in Alzheimer's disease (AD) (3 arms), sponsored by Sanofi. Primary endpoint: Safety and tolerability. Started Jun 2006; status: completed.
02
Drugs
OPNT004
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2006-002317-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002317-12.